€98.35
0.66% yesterday
Paris, Nov 15, 05:37 pm CET
ISIN
FR0013280286
Symbol
BIM
Sector

bioMerieux SA Stock price

€98.35
-8.05 7.57% 1M
+2.40 2.50% 6M
-2.25 2.24% YTD
+1.29 1.33% 1Y
-12.45 11.24% 3Y
+21.55 28.06% 5Y
+69.95 246.30% 10Y
Paris, Closing price Fri, Nov 15 2024
-0.65 0.66%
ISIN
FR0013280286
Symbol
BIM
Sector

Key metrics

Market capitalization €11.60b
Enterprise Value €11.90b
P/E (TTM) P/E ratio 28.22
EV/FCF (TTM) EV/FCF 76.07
EV/Sales (TTM) EV/Sales 3.13
P/S ratio (TTM) P/S ratio 3.05
P/B ratio (TTM) P/B ratio 3.00
Dividend yield 0.86%
Last dividend (FY23) €0.85
Revenue growth (TTM) Revenue growth 2.85%
Revenue (TTM) Revenue €3.81b
EBIT (operating result TTM) EBIT €487.20m
Free Cash Flow (TTM) Free Cash Flow €156.40m
EPS (TTM) EPS €3.48
P/E forward 24.99
P/S forward 2.96
EV/Sales forward 3.04
Show more

Is bioMerieux SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

bioMerieux SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a bioMerieux SA forecast:

12x Buy
75%
3x Hold
19%
1x Sell
6%

Analyst Opinions

16 Analysts have issued a bioMerieux SA forecast:

Buy
75%
Hold
19%
Sell
6%

Financial data from bioMerieux SA

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
3,807 3,807
3% 3%
100%
- Direct Costs 1,790 1,790
1% 1%
47%
2,016 2,016
4% 4%
53%
- Selling and Administrative Expenses 716 716
7% 7%
19%
- Research and Development Expense 474 474
2% 2%
12%
826 826
3% 3%
22%
- Depreciation and Amortization 339 339
3% 3%
9%
EBIT (Operating Income) EBIT 487 487
8% 8%
13%
Net Profit 411 411
7% 7%
11%

In millions EUR.

Don't miss a Thing! We will send you all news about bioMerieux SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The firm develops testing. detection, and other laboratory system for the analysis of cancer, diseases, and infections caused by bacteria, virus, and fungi. The company was founded Alain Mérieux in 1963 and is headquartered in Marcy l'Etoile, France.

Head office France
CEO Pierre Boulud
Employees 14,651
Founded 1967
Website www.biomerieux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today